Related Experiment Videos
In vitro evaluation of a new echographic contrast agent
Summary
A new echographic contrast agent, SHU 508 A, can cross the lung barrier, offering improved visualization of ocular vascular networks. This breakthrough expands the use of standardized echography in ophthalmology for better diagnosis and treatment evaluation.
Area of Science:
- Ophthalmology
- Medical Imaging
- Cardiology
Background:
- Intravenously injected echographic contrast agents were limited to right-sided heart studies due to inability to cross the lung barrier.
- A novel saccharide-based agent (SHU 508 A) has been developed, capable of overcoming the pulmonary barrier for potential ophthalmic applications.
Purpose of the Study:
- To compare the in vitro performance of a new pulmonary-barrier-crossing echographic contrast agent (SHU 508 A) against a conventional agent (SHU 454).
- To evaluate the potential of SHU 508 A for enhanced ocular vascular imaging.
Main Methods:
- In vitro comparison of SHU 454 and SHU 508 A diluted in saline.
- Standardized A-scan and tissue model used to assess solution reflectivity and sound attenuation.
Main Results:
- SHU 508 A demonstrated significantly higher and more prolonged reflectivity compared to SHU 454.
- No significant sound attenuation was observed with SHU 508 A.
Conclusions:
- The enhanced and sustained reflectivity of SHU 508 A facilitates detailed evaluation of normal and pathological ocular and orbital vascular networks.
- This agent expands the indications for standardized echography in ophthalmology, aiding in treatment effectiveness assessment, such as for malignant melanoma.